Stock VRDN VIRIDIAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Viridian Therapeutics, Inc.

Equities

VRDN

US92790C1045

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
14.6 USD -3.69% Intraday chart for Viridian Therapeutics, Inc. -8.12% -32.97%
Apr. 16 Foghorn Therapeutics Names Kristian Humer CFO MT
Mar. 21 B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers MT

Business Summary

Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Number of employees: 94

Sales per Business

USD in Million2022Weight2023Weight Delta
Monoclonal Antibody
100.0 %
2 100.0 % 0 100.0 % -82.28%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
2 100.0 % 0 100.0 % -82.28%

Managers

Managers TitleAgeSince
Stephen Frank Mahoney CEO
 Chief Executive Officer 53 23-10-29
Seth Harmon DFI
 Director of Finance/CFO 45 23-04-30
Thomas Ciulla CTO
 Chief Tech/Sci/R&D Officer 59 22-12-31
Thomas W. Beetham COO
 Chief Operating Officer 55 23-10-29
Angela Sheen CTO
 Chief Tech/Sci/R&D Officer - 19-12-31
Shan Wu PRN
 Corporate Officer/Principal - 23-10-29
Vahe Bedian PRN
 Corporate Officer/Principal - 20-10-27
Anthony Casciano PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Arlene Morris BRD
 Director/Board Member 72 18-01-02
Tomas Kiselak CHM
 Chairman 38 20-10-27
Stephen Frank Mahoney CEO
 Chief Executive Officer 53 23-10-29
Peter Harwin BRD
 Director/Board Member 38 20-10-27
Jennifer Moses BRD
 Director/Board Member 49 21-07-13
Sarah Gheuens BRD
 Director/Board Member 45 23-09-24

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 172,435 0 0 92.57 %
Stock B 0 143,522 0 0
Stock C 1 62,767,570 58,104,337 ( 92.57 %) 0

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
12.15 %
7,625,542 12.15 % 134 M $
Paradigm BioCapital Advisors LP
7.638 %
4,794,488 7.638 % 84 M $
Perceptive Advisors LLC
6.408 %
4,022,066 6.408 % 70 M $
Venrock Associates
6.186 %
3,882,623 6.186 % 68 M $
Deep Track Capital LP
5.786 %
3,631,728 5.786 % 64 M $
BlackRock Advisors LLC
5.190 %
3,257,350 5.190 % 57 M $
Vanguard Fiduciary Trust Co.
4.781 %
3,000,948 4.781 % 53 M $
STATE STREET CORPORATION
4.315 %
2,708,383 4.315 % 47 M $
Maverick Capital Ltd.
3.705 %
2,325,841 3.705 % 41 M $
AllianceBernstein LP
3.281 %
2,059,464 3.281 % 36 M $
NameEquities%Valuation
Fairmount Funds Management LLC
94.64 %
48,463 94.64 % 848 587 $
Deep Track Capital LP
88.93 %
45,540 88.93 % 797 405 $
Venrock Associates
43.10 %
22,073 43.10 % 386 498 $
NameEquities%Valuation
Fairmount Funds Management LLC
31.05 %
133,191 31.05 % 2 M $

Company contact information

Viridian Therapeutics, Inc.

221 Crescent Street Suite 401

02453, Waltham

+

http://www.viridiantherapeutics.com
address Viridian Therapeutics, Inc.(VRDN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Viridian Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
14.6 USD
Average target price
39.36 USD
Spread / Average Target
+169.57%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
VIRIDIAN THERAPEUTICS, INC. Stock Viridian Therapeutics, Inc.
-32.97% 952M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.42% 41.35B
LONZA GROUP AG Stock Lonza Group AG
+42.15% 40.38B
MODERNA, INC. Stock Moderna, Inc.
+1.97% 39.05B
CELLTRION, INC. Stock Celltrion, Inc.
-14.19% 26.67B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+1.82% 24.07B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.55% 18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-4.07% 11.68B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+21.36% 11.6B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.20% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. VRDN Stock
  4. Company Viridian Therapeutics, Inc.